Efficacy of a biobehavioral intervention for hot flashes: A randomized controlled pilot study

Menopause

Volumn 24, Issue 7, 2017, Pages 774-782

  Barton, Debra L ^a   Schroeder, Kelliann C Fee ^b   Banerjee, Tanima ^a   Wolf, Sherry ^b   Keith, Timothy Z ^c   Elkins, Gary ^d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^d BAYLOR UNIVERSITY   (United States)

Author keywords

Breast cancer survivorship; Hot flashes behavioral intervention; Hot flashes drug therapy; Hot flashes hypnosis; Hot flashes nonpharmacologic treatment; Menopause; Postmenopause; Quality of life

Indexed keywords

PLACEBO; VENLAFAXINE; ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BLURRED VISION; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE TITRATION; DRUG EFFICACY; FATIGUE; FEMALE; HOT FLUSH; HUMAN; HYPNOSIS; INCREASED APPETITE; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MIDDLE AGED; NAUSEA; PATIENT SATISFACTION; PILOT STUDY; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SLEEP; SOMNOLENCE; SWEATING; XEROSTOMIA; BEHAVIORAL SCIENCE; DOUBLE BLIND PROCEDURE; MULTIMODALITY CANCER THERAPY; PROCEDURES; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BIOBEHAVIORAL SCIENCES; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; FEMALE; HOT FLASHES; HUMANS; HYPNOSIS; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; VENLAFAXINE HYDROCHLORIDE;

EID: 85014529987     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000837     Document Type: Article

References (47)

1. Stearns V, Ullmer L, Lopez JF, Smith Y, Isaacs C, Hayes D. Hot flushes. Lancet 2002;360:1851-1861.
2. Gracia CR, Freeman EW. Acute consequences of the menopausal transition: the rise of common menopausal symptoms. Endocrinol Metab Clin N Am 2004;33:675-689.
3. Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: a meta-analysis. J Gen Intern Med 2008; 23:1507-1513.
4. Col NF, Guthrie JR, Politi M, Dennerstein L. Duration of vasomotor symptoms in middle-aged women: a longitudinal study. Menopause 2009;16:453-457.
5. Carpenter JS, Johnson D, Wagner L, Andrykowski M. Hot flashes and related outcomes in breast cancer survivors and matched comparison women. Oncol Nurs Forum 2002;29:E16-E25.
6. Bardia A, Novotny P, Sloan J, Barton D, Loprinzi C. Efficacy of nonestrogenic hot flash therapies among women stratified by breast cancer history and tamoxifen use: a pooled analysis. Menopause 2009; 16:477-483.
7. Marino JL, Saunders CM, Emery LI, Green H, Doherty DA, Hickey M. Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history. Menopause 2014;21:267-274.
8. Mao JJ, Chung A, Benton A, et al. Online discussion of drug side effects and discontinuation among breast cancer survivors. Pharmacoepidemiol Drug Safety 2013;22:256-262.
9. Morales L, Neven P, Timmerman D, et al. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients. Anticancer Drugs 2004;15:753-760.
10. Hunter M, Rendall M. Bio-psycho-socio-cultural perspectives on menopause. Best practice and research. Clin Obstet Gynaecol 2007;21:261-274.
11. Carpenter JS. The Hot Flash Related Daily Interference Scale: a tool for assessing the impact of hot flashes on quality of life following breast cancer. J Pain Symptom Manage 2001;22:979-989.
12. Brown L, Bryant C, Judd FK. Positive well-being during the menopausal transition: a systematic review. Climacteric 2015;18:456-469.
13. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005;3:47.
14. Greendale GA, Reboussin BA, Hogan P, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. Obstet Gynecol 1998;92:982-988.
15. Manson JE, Kaunitz AM. Menopause management: getting clinical care back on track. N Engl J Med 2016;374:803-806.
16. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
17. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-2063.
18. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20:1578-1583.
19. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23:6919-6930.
20. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-2834.
21. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. JAMA 2011;305:267-274.
22. Barton DL, Lavasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278-3283.
23. Loprinzi CL, Sloan J, Stearns V, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 2009;27:2831-2837.
24. Guttuso T Jr, Kurlan R, Mcdermott MP, Kieburtz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337-345.
25. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebocontrolled trial. Lancet 2005;366:818-824.
26. Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 2016;375:209-219.
27. Hunter MS, Grunfeld EA, Mittal S, et al. Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology 2004;13:769-778.
28. Elkins GR, Barabasz AF, Council JR, Spiegel D. Advancing research and practice: the revised APA Division 30 definition of hypnosis. Int J Clin Exp Hypnosis 2015;63:1-9.
29. Elkins G, Marcus J, Stearns V, et al. Randomized trial of a hypnosis intervention for treatment of hot flashes among breast cancer survivors. J Clin Oncol 2008;26:5022-5026.
30. Elkins GR, Fisher WI, Johnson AK, Carpenter JS, Keith TZ. Clinical hypnosis in the treatment of postmenopausal hot flashes: a randomized controlled trial. Menopause 2013;20:291-298.
31. Elkins GR. Handbook of Medical and Psychological Hypnosis: Foundations, Applications, and Professional Issues. New York: Springer Publishing Inc; 2016.
32. Sloan JA, Loprinzi CL, Novotny PJ, Barton DL, Lavasseur BI, Windschitl H. Methodologic lessons learned from hot flash studies. J Clin Oncol 2001;19:4280-4290.
33. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996;24:161-175.
34. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. Revised. Publication Adm 76-338. Washington DC: US Department of Health, Education, and Welfare; 1976.
35. Ramaswami R, Villarreal MD, Pitta DM, Carpenter JS, Stebbing J, Kalesan B. Venlafaxine in management of hot flashes in women with breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 2015;152:231-237.
36. Mahon SM, Kaplan M. Placebo effect in hot flush research. Lancet Oncol 2012;13:e188, author reply e190.
37. Maclaughlan David S, Salzillo S, Bowe P, et al. Randomised controlled trial comparing hypnotherapy versus gabapentin for the treatment of hot flashes in breast cancer survivors: a pilot study. BMJ Open 2013; 3:e003138.
38. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015;22:1155-1174.
39. Mann E, Smith MJ, Hellier J, et al. Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): a randomised controlled trial. Lancet Oncol 2012;13: 309-318.
40. Ayers B, Smith M, Hellier J, Mann E, Hunter MS. Effectiveness of group and self-help cognitive behavior therapy in reducing problematic menopausal hot flushes and night sweats (MENOS 2): a randomized controlled trial. Menopause 2012;19:749-759.
41. Duijts SF, Van Beurden M, Oldenburg HS, et al. Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 2012;30: 4124-4133.
42. Berendsen H. Hot flushes and serotonin. Menopause Int 2002;8:30-34.
43. Deecher DC, Dorries K. Understanding the pathophysiology of vasomotor symptoms (hot flushes and night sweats) that occur in perimenopause, menopause, and postmenopause life stages. Arch Women Mental Health 2007;10:247-257.
44. Slopien R, Meczekalski B, Warenik-Szymankiewicz A. Relationship between climacteric symptoms and serum serotonin levels in postmenopausal women. Climacteric 2003;6:53-57.
45. Carpenter JS, Gilchrist JM, Chen K, Gautam S, Freedman RR. Hot flashes, core body temperature, and metabolic parameters in breast cancer survivors. Menopause 2004;11:375-381.
46. Thurston RC, Christie IC, Matthews KA. Hot flashes and cardiac vagal control: a link to cardiovascular risk? Menopause 2010;17:456-461.
47. National Institutes of Health. National Institutes of Health State-ofthe-Science Conference statement: management of menopause-related symptoms. Ann Intern Med 2005;142(12 pt 1):1003-1013.